期刊
TUMOR BIOLOGY
卷 36, 期 1, 页码 55-67出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-014-2855-3
关键词
Active drug delivery; Nanotechnology; Asialoglycoprotein receptor; EGFR; Transferrin receptor; Folate receptor
类别
资金
- National Natural Science Foundation of China [81472832, 81302112, 81372663]
- Outstanding Youth Science Foundation of Tongji Hospital [YXQN005]
- Youth Sciences and Technology Chenguang Planning of Wuhan [2014070404010219]
- Fundamental Research Funds for the Central Universities [2014QN084]
Patients with hepatocellular carcinoma (HCC) usually present at advanced stages and do not benefit from surgical resection, so drug therapy should deserve a prominent place in unresectable HCC treatment. But chemotherapy agents, such as doxorubicin, cisplatin, and paclitaxel, frequently encounter important problems such as low specificity and non-selective biodistribution. Recently, the development of nanotechnology led to significant breakthroughs to overcome these problems. Decorating the surfaces of nanoparticulate-based drug carriers with homing devices has demonstrated its potential in concentrating chemotherapy agents specifically to HCC cells. In this paper, we reviewed the current status of active targeting strategies for nanoparticulate systems based on various receptors such as asialoglycoprotein receptor, transferrin receptor, epidermal growth factor receptor, folate receptor, integrin, and CD44, which are abundantly expressed on the surfaces of hepatocytes or liver cancer cells. Furthermore, we pointed out their merits and defects and provided theoretical references for further research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据